| Use of aldosterone antagonists in resistant hypertension. | |
| | |
MedLine Citation:
|
PMID: 16714158 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Resistant hypertension is defined as an elevated blood pressure in spite of treatment with 3 different antihypertensive agents. The prevalence of resistant hypertension is unknown, but recent cross-sectional analyses and hypertension outcome studies suggest it is a common clinical problem and will become even more so with an aging and increasingly heavy population. Secondary causes of hypertension are common in patients with resistant hypertension, in particular, obstructive sleep apnea and hyperaldosteronism. Treatment of resistant hypertension is predicated upon identification and reversal of secondary causes of hypertension, as possible, and effective use of multidrug regimens. Recent clinical studies indicate that aldosterone antagonists, spironolactone and amiloride, provide significant additional blood pressure reduction when added to treatment regimens of patients with resistant hypertension. Both agents are generally well tolerated. Hyperkalemia is an uncommon complication of aldosterone antagonists, but it can occur; therefore, biochemical monitoring is necessary, particularly in high-risk patients. |
| | |
Authors:
|
David A Calhoun |
Related Documents
:
|
19628318 - Association of kidney function with residual hypertension after treatment of aldosteron... 7411808 - Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. 6242558 - Antihypertensive and aldosterone-lowering effects of synthetic atrial natriuretic facto... 15854148 - The 'body fluid pressure control system' relies on the renin-angiotensin-aldosterone sy... 2522278 - Modulation of natriuresis by sympathetic nerves and angiotensin ii in conscious dogs. 19566828 - Downregulation of survival signalling pathways and increased apoptosis in the transitio... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Progress in cardiovascular diseases Volume: 48 ISSN: 0033-0620 ISO Abbreviation: Prog Cardiovasc Dis Publication Date: 2006 May-Jun |
Date Detail:
|
Created Date: 2006-05-22 Completed Date: 2006-06-20 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0376442 Medline TA: Prog Cardiovasc Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 387-96 Citation Subset: AIM; IM |
Affiliation:
|
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA. dcalhoun@uab.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
therapeutic use* Blood Pressure / drug effects* Humans Hypertension / drug therapy*, physiopathology Severity of Illness Index Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
HL 075614/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel adsorptive polyamine coating for enhanced capillary electrophoresis of basic proteins and pept...
Next Document: Systolic hypertension in older persons: how aggressive should treatment be?